List view / Grid view

HTS (High Throughput Screening)

 

article

A new small molecule drug discovery and development platform for HLA-associated autoimmune diseases

23 April 2021 | By ,

In the arsenal of approved small molecule drugs, effective, genetically-targeted therapies for the treatment of autoimmune diseases are conspicuously scarce. ImmunoMolecular Therapeutics (IM Therapeutics) has developed a paradigm for the discovery and development of new molecular entities as a broad platform for blocking genetic targets that confer risk of disease development…

product

Product Hub: High-throughput experimentation made easier with Katalyst D2D

15 May 2019 | By

Katalyst D2D is a new software application from ACD/Labs that makes the planning, execution and analysis of high-throughput, parallel experiments easier than ever before. Katalyst is a web-based digital environment that integrates with existing informatics systems, lab automation hardware, analytical instrumentation and automated execution systems for an efficient, streamlined workflow.

news

IntelliCyt Cy-Clone™ PLUS

27 March 2017 | By IntelliCyt Corporation

Cy-Clone PLUS together with the iQue Screener PLUS platform uses the power of high throughput flow cytometry...

article

Pharmaceutical salts of small molecule drugs: opportunities and challenges

28 October 2014 | By Axel Becker, Scientist, Merck KGaA

Over the past decades, pharmaceutical drug development has undergone some significant changes, a prominent example for this being the emergence of biomolecular drugs (New Biological Entities, NBEs) such as antibodies and peptides. However, classical small molecule drugs (New Chemical Entities, NCEs) are far from being a dying species, and in…

article

Laboratory Automation: Liquid handling devices in drug discovery – when, what, why?

15 December 2013 | By Sergio C. Chai, Asli N. Goktug and Taosheng Chen, High Throughput Screening Center, Department of Chemical Biology and Therapeutics, St. Jude Children’s Research Hospital

Liquid handlers are ubiquitous and essential tools in every aspect of the drug discovery arena. Innovations in the past few decades resulted in a sizeable array of devices. With so many choices, it is important to identify appropriate instrumentation for a particular screening strategy, which should be based on unique…

article

Pharmaceutical proteomics: a journey from discovery and characterisation of targets to development of high-throughput assays

15 December 2013 | By Joerg Reinders, Institute of Functional Genomics, University of Regensburg

Proteomics has evolved during the last few years from a time-intensive, cost-intensive and hard-to-reproduce technique in basic research to a versatile and reliable tool in various areas of pharmaceutical research. The exploding progress in mass-spectrometry-compatible protein and peptide-separation methods led to the development of new approaches particularly suited for monitoring…